Amarin Corp Plcuk (AMRN) Depreciation & Amortization (CF) (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Depreciation & Amortization (CF) of $1000.0 for Q2 2026, little changed year-over-year from $1000.0 in Q2 2025, and little changed quarter-over-quarter from $1000.0 in Q1 2026.
Amarin Corp Plcuk (AMRN) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $1000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) changed 0.0% year-over-year to $1000.0; the TTM figure through Jun 2026 stood at $4000.0 (down 88.57% YoY), while the FY2025 annual figure was $4000.0, down 95.92% from the prior year.
- Depreciation & Amortization (CF) held at $1000.0 in Q2 2026 per AMRN's latest filing, from $1000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $144000.0 in Q1 2022 and bottomed at $1000.0 in Q1 2025.
- Historically, Depreciation & Amortization (CF) has averaged $45277.8 across 5 years, with a median of $31500.0 in 2023.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) gained 3.23% — and 2025, when it tumbled 96.97%.
- Amarin Corp Plc\Uk's Depreciation & Amortization (CF) stood at $125000.0 in 2022, then tumbled by 73.6% to $33000.0 in 2023, then tumbled by 75.76% to $8000.0 in 2024, then tumbled by 87.5% to $1000.0 in 2025, then changed by 0.0% to $1000.0 in 2026.
- Business Quant data shows AMRN's Depreciation & Amortization (CF) at $1000.0 in Q2 2026, $1000.0 in Q1 2026, and $1000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.96 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.11 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1.62 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Jun 30, 2026 | 1,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Mar 31, 2024 | 33,000.00 |
| Mar 31, 2024 | 33,000.00 |